<DOC>
	<DOCNO>NCT01373398</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics ( PK ) intravesical instillation EO9 patient non-muscle invasive bladder cancer ( NMIBC ) .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study EO9 ( Intravesical Instillation )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Apaziquone</mesh_term>
	<criteria>Patients clinically diagnose stage Ta , T1 , histological grade G1 , G2 urothelial carcinoma bladder Patients confirm urinary cytology negative ( class I , class II ) within 4 week prior present TURBT . P.S : 02 accord ECOG . Patients primary solitary tumor . CIS lesion bladder history thereof . Grade 3 disease history thereof . Patients experience recurrence within 3 month follow TURBT prior NMIBC . Patients stage T1 highgrade disease . Invasive cancer T2 great , definite lymph node organ metastasis , history thereof . Patients receive intravesical chemotherapy/immunotherapy treatment within 6 month prior present TURBT . Patients underwent systemic chemotherapy radiotherapy whose field exposure include bladder . Patients suspect bladder perforation time present TURBT . A complication malignant tumor upper urinary tract urethra , history thereof . Malignancy within 5 year NMIBC ( except thyroid cancer ) A serious viral bacterial infection within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>EO9</keyword>
	<keyword>Apaziquone</keyword>
</DOC>